Call 203-348-8805 to discuss whether a physician-supervised plan may be appropriate
Evidence for continued use The degree of benefit reported in the study is very close to that seen in a different trial, called the SELECT study, which looked at the reduction in heart events in people taking semaglutide for obesity
This may change if demand increases and synthesis becomes feasible, but for now, access is limited to approved markets
I am not the only one who has articulated this thinking (3)
Each increment in BMI of 5 kg/m 2 greater than 22,525,0 kg/m 2 corresponds to a rise in overall mortality of 30% ( Obesity pathophysiology is multifactorial and involves social, psychological and behavioral factors, genetic and metabolic predisposition ( Obesity is directly related to the development of cardiometabolic disease (arterial hypertension, coronaric syndrome or heart failure ( Its also associated, in addition, with obstructive sleep apnea (OSAS), non-alcoholic fatty liver disease (NAFLD)/metabolic-associated fatty liver disease (MAFLD), osteoarthritis, gastro-esophageal reflux disease, malignancies (gastrointestinal, liver, breast, and endometrial cancer), and mental health issues, especially in young people
